Pharmaceutical Compatibility of Tissue Plasminogen Activator and DNase
Respiration · 24.11.2025 · 105 (5) · 595-598
DOI: 10.1159/000549731 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, online erschienen am 24.11.2025. Verfasst von Jos F Frencken und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands, j.f.frencken@gmail.com. Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, Deoxyribonucleases, Fibrinolytic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Intrapleural fibrinolytic therapy, involving the sequential administration of DNase and tissue plasminogen activator (tPA), is a key component in the management of pleural infections. This approach has been shown to reduce hospital length of stay and the need for surgical intervention. However, it remains unclear whether these agents are pharmaceutically compatible for concurrent administration. This study investigated the compatibility of DNase and tPA when mixed together.
Methods
We prepared the following combinations of tPA (Actilyse, Boehringer Ingelheim B.V.) and DNase (Pulmozyme, Roche Nederland B.V.): undiluted (10 mg tPA + 5 mg DNase), diluted in 50 mL saline, and diluted in 500 mL saline. Control solutions containing only tPA, only DNase, or only saline were also prepared. Physical stability was assessed by visual inspection for particulate formation, haze, precipitation, color change, or gas evolution. Physical compatibility was evaluated by measuring pH at baseline, 2 h, and 4 h post-preparation, at both room temperature and 40°C. Incompatibility was defined as a mean absolute pH change greater than 1 unit over time.
Results
All tested solutions remained physically compatible across all time points, dilutions, and temperatures.
Conclusion
Our findings demonstrate that tPA and DNase are pharmaceutically compatible when mixed and diluted in normal saline. This supports the feasibility of concurrent intrapleural administration, which may reduce labor intensity, improve protocol adherence, and lower the risk of iatrogenic infections in patients with pleural infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands, j.f.frencken@gmail.com.
- Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Pulmonary Medicine, Bravis Hospital, Roosendaal, The Netherlands.
Zitieren
APA
Frencken, J. F., Hassanzai, M., Hoek, R. A. S., & van der Sijs, H. H. (2025). Pharmaceutical Compatibility of Tissue Plasminogen Activator and DNase. Respiration, 105(5), 595-598. https://doi.org/10.1159/000549731
Vancouver
Frencken JF, Hassanzai M, Hoek RAS, van der Sijs HH. Pharmaceutical Compatibility of Tissue Plasminogen Activator and DNase. Respiration. 2025;105(5):595-598. doi:10.1159/000549731
BibTeX
@article{Frencken2025,
author = {Frencken, Jos F and Hassanzai, Moska and Hoek, Rogier A S and van der Sijs, Heleen H},
title = {Pharmaceutical Compatibility of Tissue Plasminogen Activator and DNase},
journal = {Respiration},
year = {2025},
volume = {105},
number = {5},
pages = {595--598},
doi = {10.1159/000549731}
}
EUVIMED